<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424837</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00088754</org_study_id>
    <nct_id>NCT03424837</nct_id>
  </id_info>
  <brief_title>A Survivorship Care Plan and Embedded Navigation Tool</brief_title>
  <acronym>ASCENT</acronym>
  <official_title>Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients With Prostate Cancer Undergoing Curative-Intent Radiotherapy With Concurrent Androgen Deprivation Therapy (ADT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Morehouse School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel group, multisite prospective clinical study. The purpose of this study is
      to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and
      improves coordination of care to address patient needs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abiding by the survivorship guidelines as measured by making an appointment within 6 months of enrollment OR completing a guideline-based assessment.</measure>
    <time_frame>6 months</time_frame>
    <description>Abiding by the survivorship guidelines is defined as either of: Making an appointment with primary health care provider within 6 months of enrollment, OR completing a guideline-based assessment or management strategy for reducing side effects related to prostate cancer treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General health status</measure>
    <time_frame>6 months</time_frame>
    <description>General health status will be measured using the EuroQol five dimensions questionnaire (EQ-5D).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Existence and severity of depression</measure>
    <time_frame>6 months</time_frame>
    <description>Existence and severity of depression will be evaluated using the Patient Health Questionnaire (PHQ-9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-cancer specific quality of life.</measure>
    <time_frame>6 months</time_frame>
    <description>Prostate-cancer specific quality of life will be determined using the Expanded Prostate Cancer Index Composite - Short Form (EPIC-26).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall health-related-quality of life including, but not limited to, mental and physical functioning as measured by the Short Form Health Survey</measure>
    <time_frame>6 months</time_frame>
    <description>Overall health-related-quality of life will be measured using the Short Form Health Survey (SF-12).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention Arm: SoC and ASCENT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Health care per institutional standard plus ASCENT via the TrueNTH website.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm: SoC and TrueNRH</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise &amp; diet, and lived experiences modules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ASCENT</intervention_name>
    <description>ASCENT includes the following components:
Survivorship care plan created through the ASCENT tool
Online tool which assesses health care needs and facilitates receipt of care
A national-level navigator who helps the participant to access support services
Periodic reminders for the participant to pursue recommended survivorship care</description>
    <arm_group_label>Intervention Arm: SoC and ASCENT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of prostate adenocarcinoma

          -  Age ≥18 years

          -  Receiving curative intent radiotherapy for prostate cancer (Note: post-operative
             radiotherapy [i.e., &quot;adjuvant&quot; or &quot;salvage radiotherapy subsequent to prostatectomy]
             is allowed.)

          -  Subjects will be enrolled within two weeks prior to and two weeks after the final
             fraction of radiotherapy.

          -  Receiving androgen deprivation therapy (ADT) for a duration of ≥3 consecutive months
             as follows:

               -  GnRH agonist or antagonist (medical castration), with or without an anti-androgen
                  (i.e., bicalutamide, flutamide, nilutamide, etc.), OR

               -  Bilateral orchiectomy (surgical castration)

          -  Technology requirement: candidates must have access to the internet

          -  Able to understand and willing to sign a written informed consent document.

          -  Able to speak and understand English, in the opinion of the treating physician.

        Exclusion Criteria:

          -  Significant concurrent medical or psychiatric condition that would interfere with the
             patient's ability to abide by the study protocol or cooperate fully with the protocol
             requirements, including completion of survey and assessment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Harrison, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Peterson, M.D.</last_name>
    <phone>919-684-2516</phone>
    <email>drew.peterson@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eileen Lanham</last_name>
    <phone>919-668-2314</phone>
    <email>lanha001@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Compitello</last_name>
      <phone>813-745-8343</phone>
      <email>Rachel.compitello@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Scott Gilbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University &amp; Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theresa W Gillespie, PhD, MA</last_name>
      <phone>404-778-4617</phone>
      <email>tgilles@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa W Gillespie, PhD, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of medicine &amp; Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig Pollack</last_name>
      <phone>410-502-2359</phone>
      <email>Cpollac2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Pollack, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Connors</last_name>
      <phone>617-632-5592</phone>
      <email>Christine_connors@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Partridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley McGregor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Le, RSA</last_name>
      <phone>646-888-8269</phone>
      <email>let@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Sigrid Carlsson, MD,PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Vickers, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Chen</last_name>
      <phone>984-974-8428</phone>
      <email>Ronald_chen@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tony Drier, RA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eileen Lanham</last_name>
      <phone>919-668-2314</phone>
      <email>lanha001@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Harrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

